2. Data Management Working Party Report



Similar documents
Rational for secondary prophylaxis in VWD

NHS Lanarkshire Information Governance Committee

FREQUENTLY ASKED QUESTIONS (FAQ)

INFORMATION GOVERNANCE POLICY

Appendix 1 Business Case to Support the Relocation of Mental Health Inpatient Services in Manchester (Clinical Foreword and Executive Summary)

ADVISORY COMMITTEE ON DANGEROUS PATHOGENS Annex M guidance

Evaluation of the first year of the Inner North West London Integrated Care Pilot. Summary May In partnership with

NATIONAL STATISTICS TO MONITOR THE NHS CANCER PLAN - REPORT OF A PRE SCOPING STUDY

NHS BLOOD AND TRANSPLANT

Policy for Care Quality Commission Essential standards of quality and safety self assessment and assurance process

Demographic Batch Search (DBS)

Data Quality Policy. The Trust will aim to achieve and maintain the highest standards contained within the Information Governance Toolkit.

Patient Participation Directed Enhanced Service 2012/13

Life Insurance. What you need to know about. Mucopolysaccharide and related diseases including Fabry disease

JOB TITLE: Data Quality/IT Manager

Foto MCristof for SMC media. Italy 24February. www. eahad org. 5th EAHAD. European Association for Haemophilia and Allied Disorders

YORK HOUSE MEDICAL CENTRE PPG REVIEW 2013/2014. Prepared 24 March 2014

A step by step introduction to setting up and running a successful nurse-led clinic in practice

Information for people who have an increased risk of Creutzfeldt-Jakob disease (CJD)

Haemophilia Nurse Specialist Outreach Post. Dympna Cawley Assistant Director of Nursing OLCHC

THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR)

State of medical education and practice in the UK: Name: Dr. Judith Hulf Senior Medical Adviser to the GMC

University of Utah CME Statement

TAXREP 01/16 (ICAEW REP 02/16)

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

Information Governance Plan

NHS Business Services Authority (NHSBSA) Data Analytics Programme

RECORDS MANAGEMENT POLICY

Genito-urinary Medicine

Putting information at the heart of nursing care. How IT is set to revolutionise health care and the NHS

PATIENT ACCESS POLICY V3

HEALTHWATCH AND NHS COMPLAINTS ADVOCACY AN UPDATE ON THE IMPLEMENTATION OF SERVICES IN BEXLEY

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Guidance document for EMIS Web EPS Release 2 deployment

Careers in Haematology

Best Practice. Change Management. Guidelines

Executive Summary and Recommendations: National Audit of Learning Disabilities Feasibility Study

BRITISH DERMATOLOGICAL NURSING GROUP

Shropshire Community Health Service NHS Trust Policies, Procedures, Guidelines and Protocols

JOB DESCRIPTION. Specialist Hospitals, Women & Child Health Directorate. Royal Belfast Hospital for Sick Children

The maternity pathway payment system: Supplementary guidance

AUDIT COMMITTEE TERMS OF REFERENCE

Caroline Flynn, Elaine Horgan and Christine Taylor

Appendix D- Monoclonal Gammopathy of Undetermined Significance (MGUS)

Customer Guide Helpdesk & Product Support. [Customer Name] Page 1 of 13

Department of Health/ Royal College of General Practitioners. Implementing a scheme for General Practitioners with Special Interests

NHS England Equality Information Patient and Public Focus First published January 2014 Updated May 2014 Publication Gateway Reference Number: 01704

Joint Surrey Carers Commissioning Strategy for 2012/3 to 2014/5 Key Priorities for Surrey Multi Agency Delivery Plan - May 2012

South East Water Corporation Finance Audit and Risk Management Committee Charter. October 2012

Irish Haemophilia Society. Introduction to Haemophilia. Brian O Mahony November 2009

HSCIC Audit of Data Sharing Activities:

Whitehall II Data Collection Procedure Phases 11 and 12

GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST

Annex D: Standard Reporting Template

Public Records (Scotland) Act Healthcare Improvement Scotland and Scottish Health Council Assessment Report

Intermediate Level Laparoscopic Surgery

Policy and Procedure for Claims Management

Harness Care Cooperative Ltd Quality primary care services provided through local cooperation Company registration:

INTRODUCTION TO THE UK CURRICULUM IN CLINICAL GENETICS

Clinical Governance and Workforce Committee Summary Report

1.1 Terms of Reference Y P N Comments/Areas for Improvement

2. Which clinical records should be included in hospital data submission?

HEALTH AND SAFETY IN SCHOOLS A GUIDE FOR TEACHERS. Ulster Teachers Union 94 Malone Road Belfast BT9 5HP. office@utu.

SCHEDULE OF THIRD PARTIES WITH WHOM THE TRUST HAS A DUTY OF CO-OPERATION

Revalidation of nurses and midwives

Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System

INFORMATION LEAFLET. If anything is not clear, or if you would like more information, please

GUIDE BOOK FOR PROGRAMME HUBS AND SCREENING CENTRES. NHS Bowel Cancer Screening Programme Version 3 31 March 2008

Revision of the Directive 98/79/EC on In Vitro Diagnostic Medical Devices. Response from Cancer Research UK to the Commission August 2010

Use and verification of the NHS number for all active patients.

The 100,000 genomes project

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

CONTROLLED DOCUMENT. Number: Version Number: 4. On: 25 July 2013 Review Date: June 2016 Distribution: Essential Reading for: Information for:

Outpatient Survey 2011

NON CONSULTANT CAREER GRADE DOCTORS AN IMPORTANT PART OF THE PAEDIATRIC WORKFORCE

AVOIDING UNPLANNED ADMISSIONS ENHANCED SERVICE: PROACTIVE CASE FINDING AND CARE REVIEW FOR VULNERABLE PEOPLE GUIDANCE AND AUDIT REQUIREMENTS

Guidance Statement GS 011 Third Party Access to Audit Working Papers

The power of information: Putting all of us in control of the health and care information we need (Department of Health)

The practice of medicine comprises prevention, diagnosis and treatment of disease.

Transcription:

2. Data Management Working Party Report Membership Dr Gerry Dolan Lorraine Birtwhistle Dr Paula Bolton-Maggs Nancy Brodie Dr Peter Collins Lynne Dewhurst Bridget Emanuel Dr Charles Hay Prof Frank Hill Dr Sybil Hirsch Dr Rob Hollingsworth Prof Christopher Ludlam Mick O Donnell Prof John Pasi Margaret Unwin Clifford Welch Dr Mike Williams Chairman Haemophilia Nurses Association Representative Rare Haemostatic Defects Working Party UK Haemophilia Data Managers Forum Inhibitor Working Party Working Party Secretary London Commissioners Chairman UKHCDO vcjd and Transfusion Transmitted Infections Working Party NHD Project Manager Software Engineer Genetics Working Party West Midlands Commissioner Von Willebrand's Working Party Haemophilia Society Patient Representative Paediatric Working Party Remit The working group oversees the management and activities of the National Haemophilia Database and has special responsibility for the development of the database and the patient information system. The group met twice during the year at Manchester Royal Infirmary and, in addition, several conference telephone calls were convened. The National Haemophilia Database The National Haemophilia Database (NHD) has made considerable progress in 2005/6 and has been the cornerstone to major national Haemophilia service projects (Recombinant Rollout, National Procurement, vcjd Surveillance, etc.) and research. These projects illustrate the vital role that the NHD fulfils for the Haemophilia service and commissioning. Finance Funding for NHD has been from grants from the Department of Health and an increasing proportion from commissioners. The latter funding stream now accounts for approximately 40% of financial support for the database and there is the opportunity to secure further support from commissioners. Software support and software development continues to be provided on a consultancy basis. Finance for support of the Haemophilia Clinical Information System (HCIS) is provided from maintenance charges to Haemophilia Centres. Funding for the 2007 year is as yet not confirmed but it is hoped it will be again come from a combination of sources as above. 1

Staffing The NHD Project Manager, Dr Sybil Hirsch is responsible for core data collection and analysis and is assisted by our administrative assistant, Ms Lynne Dewhurst. Software support for NHD, HCIS and various projects is provided by a team (Paul Kane, Enis Muminovic and Amir Rowaichi) led by Dr Rob Hollingsworth. In recent months, a further administrative assistant Ms Jessica Smith has been appointed to develop work on the collection of data on potential exposure to vcjd in patients with haemophilia. This post has been funded by a grant from the DoH. There are future plans to expand the research capacity of the database and this may involve employment of extra research staff depending on the volume of research projects. Continued Development of the National Haemophilia Database The NHD has undergone significant developments this year. This includes a large expansion of the available dataset, bringing the data up to date (previously one year behind) and large-scale validation exercises to validate and improve existing data held. The major difficulties encountered during 2004 and 2005 in relation to centre access to the electronic NHD (caused by redevelopment of NHS IT infrastructure) have largely been resolved. NHD Dataset Expansion The NHD dataset has been expanded to include patient specific data such as GP Practice Code, NHS number and Post Code. As well as these additional data items, for the first time the NHD is now recording product usage by individual patient. Previously product usage was only available by diagnosis. These additions open up whole new areas of potential audit, research and reports (patient usage, regional breakdowns, PCT specific etc.). The vcjd project has also resulted in an expansion of the dataset to store the vcjd related information. It has been decided that next year we will have a transitional year moving towards reporting of data by financial rather than calendar year. NHD Data Brought Up to Date This year we have taken steps to make the data held within the NHD current (data previously one year out of date). This has involved carrying out annual data collection and reports for both 2004 and 2005. This has been a major undertaking but has key benefits for both the quality and usefulness of the data within the NHD for commissioning and research purposes. New Technologies New technologies such as web services have been developed in order to integrate the NHD more closely with the locally implemented Haemophilia Centre-based system (HCIS). These include automated services to notify centres of deaths of patients that they have registered as being seen at their centres, automated submission of NHD returns data, automated registration of patients on the NHD etc. HCIS and these technologies are the key to achievable increases in 2

detail levels of data available to the NHD. Centre use of the HCIS system is essential in order to continue to expand the dataset and detail of information collected for the NHD. Validation Exercises Combined with these developments we have undertaken data validation exercises to validate and improve the quality of existing data within the NHD. This validation has included a national validation of patient factor levels by Haemophilia Centres, use of the NHS Strategic Tracing Service (NSTS) to validate and insert GP Practice Codes, NHS numbers, Date of Birth, Date of Death and Post Codes. Regular validation using NSTS will ensure NHD data is always up to date, accurate and complete. Service Level Agreement (SLA) The NHD has been working closely with the Pan Thames Haemophilia Consortium (PTHC) to enhance the dataset, define data access mechanisms and design reports specifically tailored for commissioners. Pan Thames have requested monthly reports for specific data items. An early outcome of these discussions is that the NHD will now move to recording data in financial year format (for 06-07 onwards) to increase the usefulness of current NHD data for commissioners. The reports and additional dataset items established by these discussions will enable commissioners to better plan, manage and forecast their commitments to the Haemophilia Service. Use of the NHD is the only way to obtain data that enables both long and short term planning, through activities such as analysis of trends, time activity comparisons, and identification of outliers. It is hoped that these reports will start during the current financial year and be extended and develop in the next financial year. The Haemophilia Clinical Information System (HCIS) HCIS is recommended by the UKHCDO for centres who wishing to acquire a centre data management system. The rollout of the system continues and has been installed in 21 Haemophilia Centres to date with several more planned. The structured support for the system continues with an established user s forum, national training days and a comprehensive support web site. The system continues to be enhanced to reflect the changing needs of centres e.g. Home Delivery. This year we will be looking closely at incorporating product bar code reading facilities and closer integration with home delivery providers to reduce the required workload for centres to deliver these services. The web service technologies as described have dramatically eased the workload required to register patients on the NHD, submit annual returns and register patient deaths. We will be looking to make more use of these technologies during 2007 to provide functionality such as automated updates of the HCIS system. A new genetics dataset established by the genetics WP is close to completion and this will be incorporated into HCIS, allowing electronic image storage of patient genetic reports. 3

Automated Data Collection from the Haemophilia Clinical Information System Following the successful pilot work in four centres for semi automatic data export for the 2003 returns, this system has been rolled out to almost all HCIS centres with great success. This facility has dramatically reduced the effort required to produce this years returns data requirements for 2004 and 2005. UKHCDO Website The UKHCDO website is maintained at http://www.ukhcdo.org. The website is updated regularly and has details of all meetings and all relevant information for the working parties. Dataset Changes Details of the updated dataset are given in Appendix I. Key changes to the dataset through 2005/6 are: - Collection of GP code. Next year we intend to move over to reporting by financial year rather than calendar year. Adverse event reporting The monthly orange e-mail is being introduced in 2007 and this will allow real-time entry of adverse events. Early feedback on pilots has been positive and it is hoped that it will both speed up and enhance the completeness of adverse event reporting. Research Proposals UKHCDO has acknowledged the potential of the database to support research in Haemophilia and related conditions in the UK. It has been agreed that the Working Parties and other researchers in the UK should have easier access to the database. A protocol for requesting data will be presented at this AGM for approval. All requests for information will be processed in compliance with the Data Protection Act of 1998. Data Protection Act and Caldicott Inspection A new patient information leaflet is about to be printed, and it has been agreed that we will post this to patients. A Caldicott inspection was undertaken in February 2006. Two minor issues were raised and were immediately resolved with the inspector. We have also had further correspondence with the Data Protection Registrar confirming our compliance with DPA 4

Freedom of Information Act The Freedom of Information Act does not apply to registered charities and so we are not obliged to release old minutes under the provisions of the act. No requests of this sort have been received for nine months. Data Managers Forum The group of Haemophilia Centre Data Managers continues to provide valuable feedback and support for the NHD and HCIS. Nancy Brodie continues in the role of chairman and is a member of the working party. Lynne Dewhurst continues as secretary. Summary The changes in HCIS have greatly improved the ability to provide and collect data. This has allowed a catch up in the annual returns to the point where, with this double report, the data are up to date. This has been achieved despite a greatly expanded dataset and several other high pressure activities such as the national procurement project, recombinant for all rollout and audit and the vcjd surveillance project. I would like to pay tribute to Charlie Hay, Sybil Hirsch, Lynne Dewhurst, Rob Hollingsworth and colleagues and to all Haemophilia Centre Data Managers for their enormous efforts to maintain, develop and extend the UKHCDO database which remains the most comprehensive haemophilia database available. Dr Gerry Dolan Chairman, Data Management WP November 2006 5

Appendix I National Haemophilia Database Data Set We are required to collect the following Data by the DoH. In the past, they have also required us to collect data on HIV but not hepatitis C. We have recently been asked to collect detailed data on potential vcjd exposure including batch numbers and volumes used. This data collection is ongoing and since entries will have to include all registered patients, even those never treated with blood products as well as those affected, it involves more than 20,000 patients. Data entry into the database will commence shortly. Name NB: It is important to note that, with a very few exceptions, we have never held central data on factor VIII/IX product batch numbers used by patients. Neither have we ever held data on hepatitis C status. Since these two items are the commonest focus of interest from patients requesting extracts from the database, it is important to emphasise this limitation in the historical dataset. Name Soundex General patient information FIELD NAME Sex Basic factor level EXPLANATION Male or Female Factor level for the diagnosed deficiency DOB Year First Registered Inhibitor detected Year Inhibitor First Detected Year first registered with the NHD Year of first inhibitor detection Inhibitor form received and date HB s AG Carrier Resident Overseas Date of Death Cause of Death History of Jaundice/Hepatitis NHS number Old NHS No Oxford Diagnosis No longer used 6

Oxford Reg No No longer used Home Post Code GP Practice code Date of Death - Not known at Centre Cause of Death - Not known at Centre Used if information is obtained from source other than a Haemophilia Centre Used if information is obtained from source other than a Haemophilia Centre Annual Treatment Record FIELD NAME EXPLANATION Treatment Year Centre Regular Home Treatment Regular Prophylaxis No Inhibitor This Year Inhibitor Present This Year No Dose This Year Visitor Centre from which treatment was issued Other Use Material used Volume of Material used Record of Haemophilia Centres that each patient is registered at (patients can be registered at more than one Haemophilia Centre) FIELD NAME Centre Gene Mutation Known Gene Mutation Date No Longer Seen No Longer Seen - Date Date Registered EXPLANATION Name of Haemophilia Centre Date mutation detected used when patients transfer Date Date registered at individual Haemophilia Centres Date first seen Date first seen at individual Haemophilia Centres 7

vwd results FIELD NAME EXPLANATION Date Code Centre Name of Haemophilia Centre Year First Seen Reason First Seen Date Form Completed Home Area VIII:C R VIII:C D VIIIR:Ag R VIIIR:Ag D VIIIRiCof R VIIIRiCof D VIIIRiCof Inhib R VIIIRiCof Inhib D 2 DIE R 2 DIE D BT mins R1 BT mins R2 BT mins D BT Method R BT Method D Severity Classification Family History Clinical Bleeding History Blood Group 1 Blood Group 2 Blood Group Date VWF:Ag VWF:Activity VWF:Ag Inhib 8

Platelet Count RPA VW Type Multimeric Analysis Platelet VWF Levels Binding Assays Mutational Analysis VW(iii) Collagen Activity ac Ripa HIV Test Date Code Centre Name of Haemophilia Centre Date of Sample Result Pos / Neg Date Form Completed Not Yet Tested Date Last Negative Date First Positive Condition Date Condition Diagnosed Date of Last Report Reporting Centre CDSC Number Comment 9

vcjd Data At Risk Status At risk or Not at risk Reason at risk Patient notified date Assessor Assessment date Batch vial size, number and release date Batch first dose Batch last dose Batch Total dose Batch brand name 10